Literature DB >> 21239774

Prognostic markers and stratification of chronic lymphocytic leukemia.

Richard R Furman1.   

Abstract

Chronic lymphocytic leukemia (CLL) is one of the most common lymphoid malignancies and is characterized by a tremendously variable clinical course. Additionally, whereas the median age at diagnosis is 72 years, CLL is diagnosed with increasing frequency in younger patients. Given the toxicities associated with currently available therapies, being able to predict which patients will need treatment could play a significant role in preserving bone marrow function and reducing morbidity and mortality. While a great many prognostic markers have been identified that predict outcomes for patients with CLL. Learning how to use these prognostic markers to provide patient care is more difficult.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21239774     DOI: 10.1182/asheducation-2010.1.77

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  13 in total

1.  Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia.

Authors:  Keith Tolley; Catherine Goad; Yunni Yi; Penny Maroudas; Amin Haiderali; Gwilym Thompson
Journal:  Eur J Health Econ       Date:  2012-09-01

2.  RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.

Authors:  Jingjing Xu; Peng Zhou; Wenjuan Wang; Aining Sun; Feng Guo
Journal:  J Mol Med (Berl)       Date:  2013-09-17       Impact factor: 4.599

Review 3.  Chronic lymphocytic leukemia: inception to cure: are we there?

Authors:  Deepesh P Lad; Pankaj Malhotra; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2012-10-09       Impact factor: 0.900

4.  MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia.

Authors:  Rosa Visone; Angelo Veronese; Veronica Balatti; Carlo M Croce
Journal:  Oncotarget       Date:  2012-02

5.  Clinical relevance and treatment of nonautoimmune anemia in chronic lymphocytic leukemia.

Authors:  Stefano Molica; Rosanna Mirabelli; Matteo Molica; Luciano Levato; Francesca R Mauro; Robin Foà
Journal:  Cancer Manag Res       Date:  2011-06-01       Impact factor: 3.989

6.  Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.

Authors:  G Palermo; D Maisel; M Barrett; H Smith; G Duchateau-Nguyen; T Nguyen; R-F Yeh; A Dufour; T Robak; D Dornan; M Weisser
Journal:  Blood Cancer J       Date:  2015-10-02       Impact factor: 11.037

7.  RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia.

Authors:  Austin Y Shull; Satish K Noonepalle; Farrukh T Awan; Jimei Liu; Lirong Pei; Roni J Bollag; Huda Salman; Zhiyong Ding; Huidong Shi
Journal:  Oncotarget       Date:  2015-06-10

8.  Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.

Authors:  Monika Podhorecka; Arkadiusz Macheta; Sylwia Chocholska; Agnieszka Bojarska-Junak; Agnieszka Szymczyk; Aneta Goracy; Anna Dmoszynska; Marek Hus
Journal:  Ann Hematol       Date:  2015-12-22       Impact factor: 3.673

9.  Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemia.

Authors:  Eszter Szánthó; Harjit Pal Bhattoa; Mária Csobán; Péter Antal-Szalmás; Anikó Újfalusi; János Kappelmayer; Zsuzsanna Hevessy
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

10.  Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.

Authors:  Iwona Hus; Agnieszka Bojarska-Junak; Sylwia Chocholska; Waldemar Tomczak; Justyna Woś; Anna Dmoszyńska; Jacek Roliński
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.